Colestimide: The efficacy of a novel anion-exchange resin in cholestatic disorders

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 11, 2002, Pages 1133-1135

  Matsuzaki, Yasushi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANION EXCHANGE RESIN; BILE ACID; COLESTILAN; COLESTYRAMINE; URSODEOXYCHOLIC ACID;

BILIARY CIRRHOSIS; CHOLESTASIS; DRUG EFFICACY; EDITORIAL; GALLBLADDER DISEASE; INTESTINE ABSORPTION; PRIORITY JOURNAL; PRURITUS; SMALL INTESTINE;

EID: 0036912554     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02860.x     Document Type: Editorial

References (27)

1. Limbird LE. Bile acid-binding resins. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996; 888-9.
2. Tokyo Cooperative Gallstone Study Group. Efficacy and indication of ursodeoxycholic acid treatment for dissolving gallstones. A multicenter double blind trial. Gastroenterology 1980; 78: 542-8.
3. Osuga T, Tanaka N, Matsuzaki Y, Aikawa T. Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. Dig. Dis. Sci. 1989; 34 (Suppl. 12): 49-51.
4. Takikawa H, Yamanaka M, Miyake K et al. Ursodeoxycholic acid therapy for chronic type C hepatitis: A multi-center, dose-finding trial. Curr. Ther. Res. 1994; 55: 16-21.
5. Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; i: 834-6.
6. Matsuzaki Y, Tanaka N, Osuga T et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am. J. Gastroenterol. 1990; 85: 15-23.
7. Oka H, Toda G, Ikeda Y et al. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol. Jpn. 1990; 25: 774-80.
8. Poupon RE, Balkou B, Eschwege E, Poupon R, the UDCA Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N. Engl. J. Med. 1991; 324: 1548-54.
9. Lindor KD, Thermeau TM, Jorgensen RA, Manlinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival on patients with primary biliary cirrhosis. Gastroenterology 1996; 1110: 1515-18.
10. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary cirrhosis. Hepatology 1999; 29: 644-7.
11. Shneider BL, Dawson PA, Christie D-M, Wong MH, Suchy FJ. Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. J. Clin. Invest. 1995; 95: 745-54.
12. Schiff ER, Small NC, Dietschy JM. Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. J. Clin. Invest. 1972; 51: 1351-62.
13. Walters HC, Craddock AL, Fusegawa H, Willingham MC, Dawson PA. Expression, transport properties, and chromosomal location of organic-anion transporter subtype 3. Am. J. Physiol. 2000; 279: G1188-200.
14. Datta DV, Sherlock S. Cholestyramine for long-term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966; 50: 323-32.
15. Silverberg DS, Iaina A, Resin E, Rotzak R, Elihou HE. Cholestyramine in uremic pruritus. Br. Med. J. 1977; 1: 752-3.
16. Chanarin I, Szur L. Relief of intractable pruritis in polycythaemia rubra vera with cholestyramine. Br. J. Haematol. 1975; 29: 669-70.
17. Taha AS, Allison MC, Myara A, Trivin F, Duncan A, Russell RI. Does cholestryramine reduce the efficacy of ursodeoxycholic acid in primary biliary cirrhosis? Eur. J. Gastroenterol. Hepatol. 1994; 6: 535-8.
18. Rust C, Sauter GH, Oswald M et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxychoic acid in man. Eur J. Clin. Invest. 2000; 30: 135-9.
19. De Simone R, Conti F, Lovanti MR. New microporous cholestyramine analog for treatment of hypercholesterolemia. J. Pharm. Sci. 1978; 67: 1695-8.
20. Zhu XX, Brown GR, St-Pierre LE. Polymeric sorbents for bile acids I: Comparison between cholestyramine and colestipol. J. Pharm. Sci. 1992; 81: 65-9.
21. Honda Y, Nakano M. Studies on adsorption characteristics of bile acids and methtrexate to a new type anion-exchange resin, colestimide. Chem. Pharm. Bull. 2000; 48: 978-81.
22. Shimada H, Mitsuka M, Umezu K. The interaction between MCI-196 and bile acids or other biological substances-comparison with cholestyramine. Jap. Pharmacol. Ther. 1996; 24: S601-606 (in Japanese with English abstract).
23. Suzuki K, Kawai M, Ksnako N, Shimada H. Study of interaction among colestimide and drugs (2nd report) - Comparison with cholestyramine. Jap. Pharmacol. Ther. 2001; 29: 37-44 (In Japanese with English abstract).
24. Tani M, Hayashi Y, Okamoto S et al. Rapid improvement of icterus and pruritus by the oral administration of colestimide in two cases of drug-induced hepatitis. Intern. Med. 2001; 40: 1048-103.
25. Yokomori H, Oda M, Ishii H. Effect of ursodeoxychokic acid and colestilan versus ursodeoxycholic acid alone on serum bile acids and pruritus: A randomized, open-label study. Curr. Ther. Res. 2001; 62: 221-9.
26. Takikawa H, Ogasawara T, Sato A, Ohashi M, Hasegawa Y, Hojo M. Effect of colestimide on intestinal absorption of ursodeoxycholic acid in men. Int. J. Clin. Pharmacol. Ther. 2001; 39: 558-60.
27. Onishi T, Sano N, Takikawa H. Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum. J. Gastroenterol. Hepatol. 2002; 17: 697-701.